Sun joins dermatology rush with $230M DUSA buyout

Dermatology is hot. Valeant Pharmaceuticals ($VRX) has been snapping up skin-remedy companies, including its recent $2.6 billion deal for Medicis. Novartis' generics unit Sandoz agreed in May to buy U.S.-based Fougera Pharmaceuticals, to become the biggest player in dermatology generics.

Now, India-based Sun Pharmaceutical is joining the party. It's buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday's closing price. The key prizes: DUSA's Levulan combination therapy, used to treat non-hyperkeratotic actinic keratoses, and BLU-U, used to treat acne.

"DUSA has proven technical capabilities in photodynamic skin treatments, with USFDA approved manufacturing," Sun Managing Director Dilip Shanghvi said in a statement. "DUSA's business brings us an entry into dermatological treatment devices, where we see good growth opportunities."

Indeed, as ICICI Direct analyst Siddhant Khandekar told Reuters, dermatology "was the only area, a growing one, where Sun did not have products in the United States. Plus, DUSA's business fits nicely with Tara Pharmaceutical, a majority-owned subsidiary that Sun is in the process of acquiring fully. "This acquisition will actually complement Taro's existing business, which has a strong dermatology product range," Khandekar said.

- see the release from Sun
- read the Reuters story

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.